VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vaxart, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026
- Market cap
- $115.15M
- P/E (TTM)
- 3.2
- Dividend yield
- –
Share price
+$0.1155 (+32.08%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Vaxart, Inc. grew revenue 201.1% to $243.06M over the twelve months to Jun 30, 2026. Free cash flow was $33.38M.
Revenue
$243.06M
+201.1% vs. a year earlier
Operating income
$39.61M
TTM Q2 2026
Free cash flow
$33.38M
TTM Q2 2026
EPS, diluted
$0.15
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $115.15M
- P/E ratio
- 3.2
- Price to sales
- 0.47
- Price to book
- 1.40
- Dividend yield
- –
- Free cash flow yield
- 28.99%
Fundamentals
- Revenue
- $243.06M
- Net income
- $38.59M
- EPS, diluted
- $0.15
- Free cash flow
- $33.38M
- Book value per share
- $0.34
- Diluted shares
- 242M
Fifteen years at a glance
Fiscal years 2008 to 2025 and trailing twelve months, USD
Revenue
$243.06M+201.1% YoY
Gross profit
–
Operating income
$39.61M
Net income
$38.59M
EPS, diluted
$0.15
Free cash flow
$33.38M
Reported periodTrailing twelve months